The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Evidence for rituximab (R) underdosing in subpopulations of elderly patients with DLBC: Results of the RICOVER-60 study of the DSHNHL.
Michael Pfreundschuh
Consultant or Advisory Role - Amgen; Merck; Onyx; Pfizer; Roche
Carsten Mueller
No relevant relationships to disclose
Samira Zeynalova
No relevant relationships to disclose
Gerhard Held
No relevant relationships to disclose
Viola Poeschel
Other Remuneration - Roche
Carsten Zwick
No relevant relationships to disclose
Marcel Reiser
No relevant relationships to disclose
Eva Lengfelder
No relevant relationships to disclose
Hjalmar B. Steinhauer
No relevant relationships to disclose
Christina Limmroth
No relevant relationships to disclose
Norbert Schmitz
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Niels Murawski
No relevant relationships to disclose